APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Duchenne Muscular Dystrophy (DMD)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026181 pages

Choose your research edition.

Industry ResearchDrugs for Duchenne Muscular Dystrophy (DMD) Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Duchenne Muscular Dystrophy (DMD) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drugs for Duchenne Muscular Dystrophy (DMD) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Drugs for Duchenne Muscular Dystrophy (DMD) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for Duchenne Muscular Dystrophy (DMD) include Bristol-Myers Squibb, Italfarmaco, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, WaVe life Science and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Drugs for Duchenne Muscular Dystrophy (DMD) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Duchenne Muscular Dystrophy (DMD) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Duchenne Muscular Dystrophy (DMD) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Drugs for Duchenne Muscular Dystrophy (DMD) market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Company

Bristol-Myers Squibb

Italfarmaco

PTC Therapeutics

Santhera Pharmaceuticals

Sarepta Therapeutics

WaVe life Science

Pfizer

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type

Eteplirsen

Deflazacort

Ataluren

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application

Home Care

Hospitals

Clinics

Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Duchenne Muscular Dystrophy (DMD) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Duchenne Muscular Dystrophy (DMD).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Drugs for Duchenne Muscular Dystrophy (DMD) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Duchenne Muscular Dystrophy (DMD) industry.

Chapter 3: Detailed analysis of Drugs for Duchenne Muscular Dystrophy (DMD) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Duchenne Muscular Dystrophy (DMD)revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Eteplirsen Table 3. Key Players of Deflazacort Table 4. Key Players of Ataluren Table 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Home Care Table 6. Key Players of Hospitals Table 7. Key Players of Clinics Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2021-2026) Table 11. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region (2027-2032) Table 13. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends Table 14. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers Table 15. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges Table 16. Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints Table 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Company (2021-2026) Table 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Company Head Office and Area Served Table 21. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company, Product Type & Application Table 22. Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Drugs for Duchenne Muscular Dystrophy (DMD) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2021-2026) Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2027-2032) Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2021-2026) Table 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2027-2032) Table 35. Bristol-Myers Squibb Company Information Table 36. Bristol-Myers Squibb Business Overview Table 37. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 39. Bristol-Myers Squibb Recent Development Table 40. Italfarmaco Company Information Table 41. Italfarmaco Business Overview Table 42. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 44. Italfarmaco Recent Development Table 45. PTC Therapeutics Company Information Table 46. PTC Therapeutics Business Overview Table 47. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 49. PTC Therapeutics Recent Development Table 50. Santhera Pharmaceuticals Company Information Table 51. Santhera Pharmaceuticals Business Overview Table 52. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 54. Santhera Pharmaceuticals Recent Development Table 55. Sarepta Therapeutics Company Information Table 56. Sarepta Therapeutics Business Overview Table 57. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 59. Sarepta Therapeutics Recent Development Table 60. WaVe life Science Company Information Table 61. WaVe life Science Business Overview Table 62. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 64. WaVe life Science Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio Table 69. Pfizer Recent Development Table 70. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026) & (US$ Million) Table 71. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032) & (US$ Million) Table 72. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026) & (US$ Million) Table 73. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032) & (US$ Million) Table 74. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) Table 76. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032) Table 77. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026) & (US$ Million) Table 78. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032) & (US$ Million) Table 79. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026) & (US$ Million) Table 80. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032) & (US$ Million) Table 81. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) Table 83. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032) Table 84. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026) & (US$ Million) Table 85. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032) & (US$ Million) Table 86. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026) & (US$ Million) Table 87. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032) & (US$ Million) Table 88. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026) & (US$ Million) Table 89. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032) & (US$ Million) Table 90. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026) & (US$ Million) Table 91. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032) & (US$ Million) Table 92. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) Table 94. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032) Table 95. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026) & (US$ Million) Table 96. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032) & (US$ Million) Table 97. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026) & (US$ Million) Table 98. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032) & (US$ Million) Table 99. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026) Table 101. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032) Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Drugs for Duchenne Muscular Dystrophy (DMD) Product Image Figure 2. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type: 2025 VS 2032 Figure 4. Eteplirsen Image Figure 5. Deflazacort Image Figure 6. Ataluren Image Figure 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application: 2025 VS 2032 Figure 9. Home Care Image Figure 10. Hospitals Image Figure 11. Clinics Image Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Type (2021-2032) Figure 21. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Application (2021-2032) Figure 23. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 24. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032) Figure 25. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032) Figure 26. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 27. United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 28. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 30. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 31. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032) Figure 32. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032) Figure 33. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 34. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 35. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 37. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 38. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 40. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 41. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032) Figure 42. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032) Figure 43. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 44. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032) Figure 45. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032) Figure 46. Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 47. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 51. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 52. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032) Figure 57. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 62. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 64. Chile Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Eteplirsen
  • Deflazacort
  • Ataluren
Applications
  • Home Care
  • Hospitals
  • Clinics
Companies covered
  • Bristol-Myers Squibb
  • Italfarmaco
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics
  • WaVe life Science
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Eteplirsen
  5. 1.2.3 Deflazacort
  6. 1.2.4 Ataluren
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Home Care
  10. 1.3.3 Hospitals
  11. 1.3.4 Clinics
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Growth Trends by Region
  14. 1.5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2021-2026)
  16. 1.5.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Dynamics
  1. 2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends
  2. 2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Drivers
  3. 2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Opportunities and Challenges
  4. 2.4 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Company (2021-2026)
  2. 3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Company Head office and Area Served
  4. 3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company, Product Type & Application
  5. 3.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Drugs for Duchenne Muscular Dystrophy (DMD) Tier 1, Tier 2, and Tier 3
4 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Type
  1. 4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2032)
  3. 4.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2021-2032)
5 Drugs for Duchenne Muscular Dystrophy (DMD) Market by Application
  1. 5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2032)
  3. 5.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Bristol-Myers Squibb
  2. 6.1.1 Bristol-Myers Squibb Company Information
  3. 6.1.2 Bristol-Myers Squibb Business Overview
  4. 6.1.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  6. 6.1.5 Bristol-Myers Squibb Recent Developments
  7. 6.2 Italfarmaco
  8. 6.2.1 Italfarmaco Company Information
  9. 6.2.2 Italfarmaco Business Overview
  10. 6.2.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  12. 6.2.5 Italfarmaco Recent Developments
  13. 6.3 PTC Therapeutics
  14. 6.3.1 PTC Therapeutics Company Information
  15. 6.3.2 PTC Therapeutics Business Overview
  16. 6.3.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  18. 6.3.5 PTC Therapeutics Recent Developments
  19. 6.4 Santhera Pharmaceuticals
  20. 6.4.1 Santhera Pharmaceuticals Company Information
  21. 6.4.2 Santhera Pharmaceuticals Business Overview
  22. 6.4.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  24. 6.4.5 Santhera Pharmaceuticals Recent Developments
  25. 6.5 Sarepta Therapeutics
  26. 6.5.1 Sarepta Therapeutics Company Information
  27. 6.5.2 Sarepta Therapeutics Business Overview
  28. 6.5.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  30. 6.5.5 Sarepta Therapeutics Recent Developments
  31. 6.6 WaVe life Science
  32. 6.6.1 WaVe life Science Company Information
  33. 6.6.2 WaVe life Science Business Overview
  34. 6.6.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  36. 6.6.5 WaVe life Science Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
7 North America
  1. 7.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
  2. 7.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
  3. 7.2.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026)
  4. 7.2.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032)
  5. 7.2.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032)
  6. 7.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
  7. 7.3.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026)
  8. 7.3.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032)
  9. 7.3.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032)
  10. 7.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
  11. 7.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  13. 7.4.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
  14. 7.4.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
  2. 8.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
  3. 8.2.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026)
  4. 8.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032)
  5. 8.2.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032)
  6. 8.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
  7. 8.3.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026)
  8. 8.3.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032)
  9. 8.3.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032)
  10. 8.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
  11. 8.4.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  13. 8.4.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
  14. 8.4.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
  2. 9.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
  3. 9.2.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026)
  4. 9.2.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032)
  5. 9.2.3 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032)
  6. 9.3 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
  7. 9.3.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026)
  8. 9.3.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032)
  9. 9.3.3 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
  2. 10.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
  3. 10.2.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026)
  4. 10.2.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032)
  5. 10.2.3 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032)
  6. 10.3 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
  7. 10.3.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026)
  8. 10.3.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032)
  9. 10.3.3 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032)
  10. 10.4 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
  11. 10.4.1 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  13. 10.4.3 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
  14. 10.4.4 Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst